Follow-The-Filings

Security

GSK

Gsk PLC · SPONSORED ADR

CUSIP 37733W204 Equity holders as of 2026 Q1 (each manager’s latest book)

13 owners 3 exits max 3.7% (Hillman Capital Managemen...)

grid → activity → earnings →
owners 13
rank #273
master % 0.13%
max % 3.7%
tracked value $8.7B
qoq A 3 R 9 E 3

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Hillman Capital Management, Inc. 2026 Q1 3.7% Reduce +0.21 pp 97,432 $5.4B hist
Dodge & Cox 2026 Q1 1.8% Reduce -0.03 pp 58,662,974 $3.2B hist
Kahn Brothers Group Inc. 2026 Q1 1.6% Reduce +0.02 pp 160,982 $9M hist
Tweedy, Browne Co. LLC 2026 Q1 0.4% Reduce +0.03 pp 81,785 $5M hist
Ray Dalio - Bridgewater Associates, LP 2026 Q1 0.2% Reduce -0.08 pp 698,666 $39M hist
Renaissance Technologies LLC 2026 Q1 0.0% Reduce -0.05 pp 311,292 $17M hist
Natixis Advisors, LLC 2026 Q1 0.0% Add +0.01 pp 254,716 $14M hist
Murray Stahl - Horizon Kinetics Asset Management LLC 2026 Q1 0.0% Reduce 0.00 pp 24,419 $1M hist
Sarah Ketterer - Causeway Capital Management LLC 2026 Q1 0.0% Reduce -0.02 pp 11,110 $613 hist
Ancora Advisors LLC 2026 Q1 0.0% Add 0.00 pp 5,317 $293 hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 36,300 $2M hist
Richard Pzena - Pzena Investment Management LLC 2026 Q1 0.0% Add 0.00 pp 18,823 $1M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce 0.00 pp 4,067 $224 hist
Steve Cohen - Point72 Asset Management, L.P. exited 2026 Q1 last 2025 Q4 0.1% Exit -0.08 pp 1,474,951 $72M hist
Ken Griffin - Citadel Advisors LLC exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 214,099 $10M hist
D. E. Shaw & Co., Inc. exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 5,544 $272 hist

13 current · 3 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · CIK 0001131399 · 25 shown

Filed Form Detail Links
6-K ADMISSION TO TRADING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS Filing Doc
6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE Filing Doc
6-K CAMLIPIXANT PHASE III RESULTS UPDATE Filing Doc
6-K AUDIT TENDER CONCLUSION Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ Filing Doc
6-K DIRECTORATE CHANGE Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K HOLDING(S) IN COMPANY Filing Doc
6-K TRANSACTION IN OWN SHARES Filing Doc
6-K HOLDING(S) IN COMPANY Filing Doc
6-K GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K TRANSACTION IN OWN SHARES Filing Doc
6-K CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA Filing Doc
6-K TRANSACTION IN OWN SHARES Filing Doc
6-K MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS Filing Doc

Updated 5 minutes ago Source: SEC EDGAR submissions All on EDGAR

ownership over time

filing count by report period · click a bar for that quarter’s holders